{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:24:15Z","timestamp":1751703855769},"reference-count":12,"publisher":"Akademiai Kiado Zrt.","issue":"29","license":[{"start":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T00:00:00Z","timestamp":1626566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,7,18]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic> A k\u00f6zelm\u00faltban publik\u00e1lt ATPCI-vizsg\u00e1lat azt\n                    eredm\u00e9nyezte, hogy k\u00f6zvetlen\u00fcl a sikeres revaszkulariz\u00e1ci\u00f3 ut\u00e1n alkalmazott\n                    trimetazidin biztons\u00e1gos volt, de nem volt effekt\u00edvebb a cardiovascularis hal\u00e1l,\n                    anginarekurrencia, cardialis hospitaliz\u00e1ci\u00f3 tekintet\u00e9ben, mint a random kett\u0151s\n                    vakm\u00f3dszerrel alkalmazott placebo. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Az \u00e1ltalunk\n                    kor\u00e1bban v\u00e9gzett ONECAPS nyitott, obszerv\u00e1ci\u00f3s vizsg\u00e1lat retrospekt\u00edv anal\u00edzis\u00e9t\n                    k\u00edv\u00e1ntuk elv\u00e9gezni annak eld\u00f6nt\u00e9s\u00e9re, hogy az angin\u00e1s betegekn\u00e9l van-e k\u00fcl\u00f6nbs\u00e9g\n                    a trimetazidin prolong hat\u00e1soss\u00e1g\u00e1ban annak megfelel\u0151en, hogy kor\u00e1bban\n                    revaszkulariz\u00e1ci\u00f3 t\u00f6rt\u00e9nt. <jats:italic>M\u00f3dszer:<\/jats:italic> 1670, angin\u00e1s betegb\u0151l 1008\n                    nem volt revaszkulariz\u00e1lva, m\u00edg 662 kor\u00e1bban revaszkulariz\u00e1ci\u00f3n esett \u00e1t. Az\n                    \u00e9letkorban, t\u00e1rsbetegs\u00e9gben nem volt k\u00fcl\u00f6nbs\u00e9g a k\u00e9t csoport k\u00f6z\u00f6tt. A\n                    betegekn\u00e9l a heti anginasz\u00e1mnak \u00e9s a nitroglicerin-fogyaszt\u00e1snak, illetve az\n                    angina s\u00falyoss\u00e1g\u00e1nak a v\u00e1ltoz\u00e1s\u00e1t vizsg\u00e1ltuk a trimetazidin prolong 80 mg napi\n                    egyszeri alkalmaz\u00e1sa sor\u00e1n a revaszkulariz\u00e1lt \u00e9s a nem revaszkulariz\u00e1lt\n                    betegcsoportban. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> Mind a revaszkulariz\u00e1lt, mind a\n                    nem revaszkulariz\u00e1lt betegcsoportban szignifik\u00e1ns cs\u00f6kken\u00e9st (p&lt;0,0001)\n                    eredm\u00e9nyezett a trimetazidin mind a heti anginasz\u00e1mban, mind a r\u00f6vid hat\u00e1s\u00fa\n                    nitroglicerin fogyaszt\u00e1s\u00e1ban. Emellett mindk\u00e9t betegcsoportban n\u00f6vekedett a\n                    Kanadai Cardiovascularis T\u00e1rsas\u00e1g (CCS) oszt\u00e1lyoz\u00e1sa szerinti I. s\u00falyoss\u00e1g\u00fa\n                    angina ar\u00e1nya, \u00e9s cs\u00f6kkent a CCS III., illetve CCS IV . ar\u00e1nya is. Mindezt a\n                    hat\u00e1st \u00fagy \u00e9rt\u00e9k el, hogy a revaszkulariz\u00e1lt betegekn\u00e9l 90% felett volt a\n                    sztatin, az ACEI\/ARB, illetve a b\u00e9ta-blokkol\u00f3 haszn\u00e1lata.\n                        <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A trimetazidin prolong napi egyszeri 80 mg\n                    ad\u00e1sa szignifik\u00e1nsan cs\u00f6kkenti a heti anginasz\u00e1mot, nitroglicerin-fogyaszt\u00e1st,\n                    illetve az angina s\u00falyoss\u00e1g\u00e1t. Ezen hat\u00e1sa f\u00fcggetlen att\u00f3l, hogy a beteg\n                    kor\u00e1bban r\u00e9szes\u00fclt-e revaszkulariz\u00e1ci\u00f3ban vagy sem. Orv Hetil. 2021; 162(29):\n                    1167\u20131171.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold>\n                    <jats:italic>Introduction:<\/jats:italic> The recently published ATPCI study resulted in\n                    the safety of trimetazidine administered immediately after successful\n                    revascularization but was not more effective (cardiovascularis death, recurrence\n                    of angina, hospitalization for cardiac event) than the randomized double-blind\n                    placebo. <jats:italic>Objective:<\/jats:italic> A retrospective analysis of our previously\n                    published ONECAPS open-label observational study was performed to determine\n                    whether there was a difference in the efficacy of trimetazidin prolong in the\n                    angina patients according to whether or not they had previously undergone\n                    revascularization. <jats:italic>Method:<\/jats:italic> Of the 1670 angina patients, 1008\n                    were not revascularized, while 662 had previously undergone revascularization.\n                    There was no difference in age or comorbidity between the two groups. Patients\n                    were examined for changes in weekly angina, short-acting nitroglycerin use and\n                    angina severity during once-daily administration of trimetazidine prolong 80 mg\n                    in revascularized and non-revascularized study groups. <jats:italic>Results:<\/jats:italic>\n                    In both the revascularized and non-revascularized group, trimetazidine resulted\n                    in a significant reduction (p&lt;0.0001) in both weekly angina count and\n                    short-acting nitroglycerin use. In addition, the proportion of angina with\n                    Canadian Cardiovascular Society (CCS) I increased and the proportion of CCS III\n                    and CCS IV decreased in both patient groups as well. All of this effect was\n                    achieved with statin, ACEI\/ARB, and beta-blocker use above 90% in revascularized\n                    patients. <jats:italic>Conclusion:<\/jats:italic> Trimetazidine prolong 80 mg once daily\n                    significantly reduced the number of angina per week, the use of short-acting\n                    nitroglycerin per week, and the severity of angina. This effect is independent\n                    of whether the patient has previously received revascularization. Orv Hetil.\n                    2021; 162(29): 1167\u20131171.<\/jats:p>","DOI":"10.1556\/650.2021.32138","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T10:06:01Z","timestamp":1630404361000},"page":"1167-1171","update-policy":"http:\/\/dx.doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":2,"title":["A trimetazidin hat\u00e1soss\u00e1g\u00e1nak \u00f6sszehasonl\u00edt\u00e1sa a revaszkulariz\u00e1lt \u00e9s a nem revaszkulariz\u00e1lt stabil angin\u00e1s betegeken a ONECAPS-vizsg\u00e1lat alapj\u00e1n"],"prefix":"10.1556","volume":"162","author":[{"given":"J\u00e1nos","family":"Tomcs\u00e1nyi","sequence":"first","affiliation":[{"name":"1 Beteg\u00e1pol\u00f3 Irgalmasrend Budai Irgalmasrendi K\u00f3rh\u00e1za, Kardiol\u00f3gia, Budapest, \u00c1rp\u00e1d fejedelem \u00fatja 7., 1025"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2018.12.015","article-title":"A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI study): rationale, design, and baseline characteristics","volume":"210","author":"1 Ferrari","year":"2019","unstructured":"1 Ferrari R, Ford J, Fox K, et al. A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI study): rationale, design, and baseline characteristics. Am Heart J. 2019; 210: 98-107.","journal-title":"Am Heart J"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0140-6736(20)31790-6","article-title":"Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomized, double-blind, placebo-controlled trial","volume":"396","author":"2 Ferrari","year":"2020","unstructured":"2 Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomized, double-blind, placebo-controlled trial. Lancet 2020; 396: 830-838.","journal-title":"Lancet"},{"key":"ref2","unstructured":"3 Tomcs\u00e1nyi J, J\u00e1nosi A, B\u00f3zsik B. ATPCI: mission impossible. Ther Adv Cardiol. 2020; 3: 16-17."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1093\/eurheartj\/ehaa865","article-title":"Weak hypothesis? Wrong pharmacological tool? Inadequate experimental design? Comment on the ATPCI trial","volume":"41","author":"Patrono C","year":"2020","unstructured":"4 Patrono C, Galiuto L. Weak hypothesis? Wrong pharmacological tool? Inadequate experimental design? Comment on the ATPCI trial. Eur Heart J. 2020; 41: 4166-4167.","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Tomcs\u00e1nyi J, Szak\u00e1cs L. Effectiveness of trimetazidine prolong in stable coronary artery disease. Multicenter, prospective, observational study, ONECAPS study. [Stabil coronariabetegs\u00e9g kezel\u00e9s\u00e9re alkalmazott trimetazidin prolong hat\u00e1soss\u00e1g\u00e1nak vizsg\u00e1lata. Multicentrikus, prospekt\u00edv, obszerv\u00e1ci\u00f3s, ny\u00edlt klinikai vizsg\u00e1lat, ONECAPS-vizsg\u00e1lat.] Orv Hetil. 2018; 159: 1549-1555. [Hungarian]","DOI":"10.1556\/650.2018.31251"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijcard.2020.01.070","article-title":"Insights from a global registry in 25 countries","volume":"311","author":"6 Brieger","year":"2020","unstructured":"6 Brieger D, Pocock SJ, Blankenberg S, et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. Int J Cardiol. 2020; 311: 7-14.","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2020.05.046","article-title":"Risk prediction tool for assessing the probability of death or myocardial infarction in patients with stable coronary artery disease","volume":"130","author":"7 Boden","year":"2020","unstructured":"7 Boden WE, Hartigan PM, Mancini J, et al. Risk prediction tool for assessing the probability of death or myocardial infarction in patients with stable coronary artery disease. Am J Cardiol. 2020; 130: 1-6.","journal-title":"Am J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0002-8703(03)00436-8","article-title":"Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease","volume":"146","author":"8 Mozaffarian","year":"2003","unstructured":"8 Mozaffarian D, Bryson CL, Spertus JA, et al. Anginal symptoms consistently predict total mortality among outpatients with coronary artery disease. Am Heart J. 2003; 146: 1015-1022.","journal-title":"Am Heart J"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9 Owlia M, Dodson JA, King JB, et al. Angina severity, mortality and healthcare utilization among veterans with stable angina. J Am Heart Assoc. 2019; 8: e012811.","DOI":"10.1161\/JAHA.119.012811"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10 Tomcs\u00e1nyi J, J\u00e1nosi I, Szak\u00e1cs L. Effectiveness of prolonged-release trimetazidine of the ONECAPS study population stratified by age. A multicenter, prospective, observational study. [Trimetazidin prolong hat\u00e1soss\u00e1ga k\u00fcl\u00f6nb\u00f6z\u0151 \u00e9letkorokban a ONECAPS-vizsg\u00e1lat alapj\u00e1n.] Cardiol Hung. 2020; 50: 206-208. [Hungarian]","DOI":"10.26430\/CHUNGARICA.2020.50.3.206"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Nagy VL, Herold Z. Clinical effect of various trimetazidine formulations in chronic coronary syndrome. [A k\u00fcl\u00f6nf\u00e9le trimetazidink\u00e9sz\u00edtm\u00e9nyek klinikai hat\u00e1sa stabil angin\u00e1val j\u00e1r\u00f3 kr\u00f3nikus koszor\u00fa\u00e9r-szindr\u00f3m\u00e1ban.] Orv Hetil. 2020; 161: 611-622. [Hungarian]","DOI":"10.1556\/650.2020.31704"},{"key":"ref11","unstructured":"12 Xu X, Zhang W, Zhou Y, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/29\/article-p1167.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/29\/article-p1167.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:12:20Z","timestamp":1698678740000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/29\/article-p1167.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,18]]},"references-count":12,"journal-issue":{"issue":"29"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32138","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,18]]}}}